Try our Advanced Search for more refined results

Idenix Pharmaceuticals LLC et al v. Gilead Sciences Inc. et al

  1. December 15, 2016

    Idenix Wins $2.5B Verdict In Gilead Hep C Drug Patent Fight

    A federal jury took less than two hours Thursday to award Idenix Pharmaceuticals LLC a $2.54 billion royalty share of Gilead Sciences Inc.'s profits from two blockbuster hepatitis C drugs, after almost nine days of courtroom battling over claims that included willful patent infringement by Gilead.

  2. December 06, 2016

    Gilead Uses Merck As Shield In $2.5B Idenix Patent Fight

    A Gilead Sciences Inc. attorney told a federal jury in Delaware on Tuesday that Merck & Co. Inc. beat Idenix Pharmaceuticals LLC to the punch on research findings that Idenix claimed as its own and is now using in a $2.5 billion hepatitis C drug infringement lawsuit against Gilead.

  3. December 05, 2016

    Idenix Seeks $2.5B In Gilead Hep C Drug Patent Dispute

    Idenix Pharmaceuticals LLC told a federal jury in Delaware Monday that it wants more than $2.5 billion from Gilead Sciences Inc. as compensation for a patent infringement "betrayal" that allegedly laid the foundation for Gilead's blockbuster hepatitis C drugs.

  4. November 23, 2016

    Idenix, Gilead To Battle Over Hepatitis IP At Trial

    Gilead Sciences Inc. and Idenix Pharmaceuticals Inc. told a Delaware federal judge Wednesday they are set to tangle over a patent related to a Hepatitis C treatment at a trial starting Dec. 5, but with only the validity of the intellectual property and possible damages at issue.

  5. January 22, 2016

    Info Still Privileged If Atty Worked As Chemist, Idenix Says

    Gilead cannot get privileged information from Idenix's former Finnegan Henderson Farabow Garrett & Dunner LLP lawyer just because of his work as a chemist, the drugmaker contended Thursday in a Delaware federal suit alleging Gilead's hepatitis C treatment flouted several Idenix patents.

  6. January 20, 2016

    Gilead Says Idenix Can't Hide Docs Behind Atty-Chemist

    Gilead Sciences told a Delaware federal judge Tuesday that Idenix Pharmaceuticals Inc. can't use the fact that one of its chemists is also a lawyer to withhold information as privileged from its suit alleging Gilead's recently approved hepatitis C treatment flouted several Idenix patents.

  7. September 17, 2014

    Finnegan Withdraws As Counsel In Hepatitis C Drug IP Row

    A Delaware federal judge on Tuesday denied Gilead Sciences' motion to disqualify Finnegan Henderson Farabow Garrett & Dunner LLP from representing Idenix Pharmaceuticals Inc. as moot in a suit accusing Gilead of flouting several Idenix patents with its hepatitis C drug after the firm withdrew.

  8. August 11, 2014

    Gilead Wants Finnegan DQ'd In Hepatitis Drug IP Row

    Gilead Sciences urged a Delaware federal judge on Friday to disqualify Finnegan Henderson Farabow Garrett & Dunner LLP from representing Idenix Pharmaceuticals Inc. in a suit alleging Gilead's recently approved hepatitis C treatment flouted several Idenix patents. 

  9. December 02, 2013

    Idenix Suits Target Gilead Hep C Drug Nearing Approval

    Idenix Pharmaceuticals Inc. told two federal courts Sunday that Gilead Sciences Inc. is on course to infringe its intellectual property if the U.S. Food and Drug Administration approves Gilead's new drug application for a Hepatitis C treatment as expected this month.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!